XENPOZYME

(Xenpozyme)

PreclinicalBiologic

GGenzyme, a Sanofi Company

XENPOZYME is one of 7 biologic programs targeting Gaucher disease type 1. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[2]

Indication

Gaucher Disease Type 1Unknown

Gaucher Disease Type 1Preclinical

Unknown

Competition

Competitive Landscape

6 competitors in Gaucher Disease Type 1

#DrugCompanyPhaseTrials

Acetadote

AArbor Pharmaceuticals, Inc.

Venglustat

1 3

Miplyffa

ZZevraDenmark

Phase 2

1 4

CEREZYME

GGenzyme, a Sanofi Company

Phase 2

1 5

Cerdelga

GGenzyme, a Sanofi Company

Phase 2

1 6

RG6026

Roche

Phase 1

—7

XENPOZYME

GGenzyme, a Sanofi Company

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Regulatory

FDA Approval Timeline[3]

Aug 31, 2022

XENPOZYME

BLA BLA761261

Sources

References

[1]
ChEMBL — Xenpozyme compound record. European Bioinformatics Institute (EMBL-EBI).
[2]
Open Targets Platform — Drug–disease associations for Xenpozyme. EMBL-EBI & Wellcome Sanger Institute.
[3]
OpenFDA — FDA approval records (BLA BLA761261). U.S. Food & Drug Administration.
[4]
SEC EDGAR — Genzyme, a Sanofi Company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[1]
Highest Phase: Preclinical
Company: GGenzyme, a Sanofi Company

XENPOZYME

Status by Indication[2]

Competitive Landscape

FDA Approval Timeline[3]

References

Drug Info

Quick Facts

Related News